Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET

Company Participants

Meredith Kaya – SVP of IR & Strategic Finance
Cedric Francois – Co-Founder & CEO
Adam Townsend – COO
Caroline Baumal – Chief Medical Officer
Tim Sullivan – CFO

Conference Call Participants

Jonathan Miller – Evercore
Tazeen Ahmad – Bank of America
Priyanka Grover – J.P. Morgan
Salveen Richter – Goldman Sachs
Yigal Nochomovitz – Citigroup
Nicholas Econom – Raymond James
Colleen Kusy – Baird
Phil Nadeau – TD Cowen
Ivy Wang – Jefferies
Eliana Merle – UBS
Annabel Samimy – Stifel
Francois Brisebois – Oppenheimer
Adam Vogel – Wells Fargo
Joseph Stringer – Needham & Company
Douglas Tsao – H.C. Wainwright
Graig Suvannavejh – Mizuho

Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised, today’s call is being recorded.

I will now turn the call over to your speaker host, Meredith Kaya, Senior Vice President, Investor Relations and Strategic Finance. Please go ahead.

Meredith Kaya

Good morning, and thank you for joining us to discuss Apellis’ first quarter 2024 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Operating Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.

Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.

Read the full article here